BRIEF published on 12/09/2025 at 14:55, 6 days 1 hour ago Teva Pharmaceuticals submits an application for authorization for Olanzapine LAI FDA Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI
BRIEF published on 12/09/2025 at 14:55, 6 days 1 hour ago Medincell and Teva Submit FDA Application for New Injectable Treatment Schizophrenia Treatment Medincell FDA Submission Teva Pharmaceuticals Olanzapine LAI
PRESS RELEASE published on 12/09/2025 at 14:50, 6 days 1 hour ago Inside Information / Other news releases Teva Pharmaceuticals submits NDA to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for Once-Monthly Schizophrenia Treatment. Medincell focuses on long-acting injectable treatments across therapeutic areas Schizophrenia Medincell Olanzapine NDA Teva Pharmaceuticals
BRIEF published on 11/11/2025 at 08:05, 1 month 4 days ago Medincell Expands Dr Grace Kim's Role to Boost US Capital Growth Biotechnology Medincell Pharmaceutical Strategy Dr Grace Kim US Capital Growth
PRESS RELEASE published on 11/11/2025 at 08:00, 1 month 4 days ago Inside Information / Other news releases Medincell appoints Dr. Grace Kim as Chief Strategy Officer, U.S. Finance to lead U.S. capital growth strategy. Medincell pioneers long-acting injectable therapies Medincell Dr. Grace Kim Long-acting Injectable Therapies U.S. Capital Growth Clinical-stage Pharmaceutical Company
BRIEF published on 11/05/2025 at 13:51, 1 month 10 days ago Continued growth for Medincell and new prospects with Olanzapine LAI Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 1 month 10 days ago Inside Information / Other news releases Medincell's partner Teva plans US NDA submission for Olanzapine LAI in Q4 2025, while UZEDY® achieves continued growth in sales in Q3 2025 Medincell Teva Pharmaceuticals Olanzapine LAI US NDA Submission UZEDY Sales Growth
BRIEF published on 10/10/2025 at 22:16, 2 months 4 days ago FDA Approves UZEDY for Bipolar I Disorder in Adults FDA Approval Mental Health Treatment UZEDY Bipolar I Disorder Risperidone
PRESS RELEASE published on 10/10/2025 at 22:11, 2 months 4 days ago Inside Information / Other news releases FDA approves UZEDY as extended-release injectable suspension for bipolar I disorder treatment in adults. Teva and Medincell collaborate on this significant advancement in neuroscience FDA Medincell Teva UZEDY Bipolar I Disorder
BRIEF published on 09/17/2025 at 14:05, 2 months 28 days ago Medincell and Teva Present Phase 3 Olanzapine LAI Data Phase 3 Trial Schizophrenia Treatment Medincell Teva Olanzapine LAI
Published on 12/15/2025 at 15:00, 1 hour 10 minutes ago Kingfisher Reports Annual General Meeting Voting Results
Published on 12/15/2025 at 15:00, 1 hour 10 minutes ago Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
Published on 12/15/2025 at 14:30, 1 hour 40 minutes ago Unusual Machines Congratulates Customers Selected for the Army's PBAS Tranche 1.1, Including Envision Technology and Strategic Logix
Published on 12/15/2025 at 14:00, 2 hours 10 minutes ago Dateline Delivers Further High-Grade Intercepts from North Pipe at Colosseum
Published on 12/15/2025 at 13:30, 2 hours 40 minutes ago Greenlane Announces Results of Annual Meeting of Stockholders, Canopy Growth Co Founder Bruce Linton Joins Greenlane's Board of Directors
Published on 12/15/2025 at 16:08, 2 minutes ago Conversion of The Platform Group AG into a KGaA completed as planned
Published on 12/15/2025 at 15:50, 20 minutes ago Original-Research: Cabka N.V. (von First Berlin Equity Research GmbH): Kaufen
Published on 12/15/2025 at 15:49, 21 minutes ago Mutares submits an irrevocable offer to acquire Venator Ultramarine Blue Pigments business from Venator France SAS
Published on 12/15/2025 at 15:45, 25 minutes ago Form 8.3 - The Vanguard Group, Inc.: Qualcomm Incorporated
Published on 12/15/2025 at 15:44, 26 minutes ago Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Published on 12/15/2025 at 11:50, 4 hours 20 minutes ago Statement about the number of shares composing the share capital and the number of voting rights as of November 30, 2025
Published on 12/12/2025 at 18:00, 2 days 22 hours ago Disclosure of trading in own shares between November 24th and November 28th, 2025
Published on 12/11/2025 at 08:30, 4 days 7 hours ago Edenred and Daimler Truck join forces to accelerate the rollout of charging infrastructure for electric trucks in Europe
